Clinical Trials Browser

Phase 1/2 × C-Met Exon 14 Mutation × glumetinib × Clear all

NCT04270591 2022-08-01

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Phase 1/2 Recruiting

C-Met Exon 14 Mutation